PD44: Bladder Cancer: Invasive VI

Monday, May 1, 2023

9:30 AM – 11:30 AM CST

Location: S502

CE: 1

Podium Session Moderator(s)

Vinata Lokeshwar, PhD (she/her/hers)

Professor and Chair Biochemistry and Molecular Biology; Professor of Urology
Medical College of Georgia, Augusta University
Brant Inman, MD, MS, FRCSC (he/him/his)

Chin-Hardie Chair of Urologic Oncology
Duke Cancer Institute

Presentations:

9:30 AM – 9:40 AM CST

PD44-01: Accuracy of Actual Stage Prediction Using Vesical Imaging-Reporting and Data System (VI-RADS) before Radical Cystectomy for Urothelial Carcinoma
Podium Presenter: Si Hyun Kim, MD,BA,MA – Soonchunhyang University Cheonan Hospital
9:40 AM – 9:50 AM CST

PD44-02: Effect of Gender on Survival Outcomes after Trimodal Therapy for Muscle-Invasive Bladder Cancer
Podium Presenter: Iain Macintyre, MD, BS – Queen's University
9:50 AM – 10:00 AM CST

PD44-03: Evaluation of gender specific differences in health-related quality of life for bladder cancer patients after radical cystectomy - Results from a large prospective propensity score-matched cohort
Podium Presenter: Thilo Westhofen
10:00 AM – 10:10 AM CST

PD44-04: Age Associated Changes to Health Related Quality of Life after Radical Cystectomy: a prospective study
Podium Presenter: Kelly R. Pekala
10:10 AM – 10:20 AM CST

PD44-05: Age Related Trends in the Utilization of Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer
Podium Presenter: Jeffrey Orf, MD
10:20 AM – 10:30 AM CST

PD44-06: Chemotherapy vs immunotherapy as neoadjuvant therapies in cisplatin-eligible patients undergoing radical cystectomy for muscle invasive bladder cancer
Podium Presenter: Luigi Nocera, MD (he/him/his) – IRCCS Ospedale San Raffaele
10:30 AM – 10:40 AM CST

PD44-07: Bowel Preparation Regimens Reduce Sepsis Following Radical Cystectomy with Continent Diversion
Podium Presenter: Kerith Ruoyao Wang, BA
10:40 AM – 10:50 AM CST

PD44-08: Benefit of Whole-Pelvis Radiation for Patients with Muscle-Invasive Bladder Cancer: An Inverse Probability Treatment Weighted Analysis
Podium Presenter: Ronald Kool, MD
10:50 AM – 11:00 AM CST

PD44-09: IMPACT OF HIGH-RISK FEATURES AND STAGING ON NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS TREATED WITH RADICAL CYSTECTOMY: A SINGLE CENTER ANALYSIS OF 1700 CASES
Podium Presenter: Shreyas Naidu, BA
11:00 AM – 11:10 AM CST

PD44-10: Association between antibiotic and treatment efficacy in urothelial carcinoma patients receiving immunotherapy or chemotherapy
Podium Presenter: Avery E. Braun, DO – UCSF
11:10 AM – 11:20 AM CST

PD44-11: Neoadjuvant Chemotherapy Increases Urinary and Bowel Anastomotic Failure in pT2-T4 Bladder Cancer Undergoing Radical Cystectomy
Podium Presenter: Young Son, DO
11:20 AM – 11:30 AM CST

PD44-12: Risk Factors of Chronic Kidney Disease Deterioration Following Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis
Podium Presenter: Alireza Ghoreifi, MD (he/him/his) – Duke University